The FDA’s Shock Indication for the Impella

April 11, 2016

The FDA recently granted Abiomed approval to expand Impella™ 2.5 PMA to treat patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. So we are very excited to speak with Dr. Bill Lombardi of University of Washington about the shock indication for the Impella┬« Platform of Devices. (Tweet This)

Subscribe to the Digital Community

Receive weekly updates including case review videos, tips and tricks, specialists opinions, and resources and downloads regarding Protected PCI and Cardiogenic Shock.